By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abcodia today said that it will collaborate with Singapore-based VolitionRx on developing biomarker-based tests for a variety of cancers.

The London-based firm said that the partnership will discover and develop diagnostic tests for lung, colorectal, and pancreatic cancer using VolitionRx's nucleosome technology. Abcodia said that it will work with VolitonRx on designing the program and identifying cohort samples from its large prospective serum biobank.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.